Related references
Note: Only part of the references are listed.Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany
Monika Engelhardt et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial
Vania Hungria et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial
Torben Plesner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study
Lene Kongsgaard Nielsen et al.
HAEMATOLOGICA (2020)
How are patient-reported outcomes and symptoms being measured in adults with relapsed/refractory multiple myeloma? A systematic review
Matthew R. LeBlanc et al.
QUALITY OF LIFE RESEARCH (2020)
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
Katja Weisel et al.
LEUKEMIA & LYMPHOMA (2020)
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
Ujjawal H. Gandhi et al.
LEUKEMIA (2019)
High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action
Homer C. Adams et al.
CYTOMETRY PART A (2019)
General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States
S. Nolte et al.
EUROPEAN JOURNAL OF CANCER (2019)
Investigating Potential Bias in Patient-Reported Outcomes in Open-label Cancer Trials
Jessica K. Roydhouse et al.
JAMA ONCOLOGY (2019)
Patient-reported outcomes of multiple myeloma patients treated with panobinostat after ≥2 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial
Paul G. Richardson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
S. K. Kumar et al.
LEUKEMIA (2017)
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari et al.
BLOOD (2017)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials
Don Robinson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis
Christina Ramsenthaler et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking
Marije B. Overdijk et al.
JOURNAL OF IMMUNOLOGY (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab in Combination with Lenalidomide Plus Dexamethasone Induces Clonality Increase and T-Cell Expansion: Results from a Phase 3 Randomized Study (POLLUX)
Christopher Chiu et al.
BLOOD (2016)
Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial
Katja Weisel et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide
Michel Delforge et al.
HAEMATOLOGICA (2015)
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
Marije B. Overdijk et al.
MABS (2015)
Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life
R. Baz et al.
SUPPORTIVE CARE IN CANCER (2015)
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide
Michel Delforge et al.
HAEMATOLOGICA (2015)
Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study
Karin Jordan et al.
SUPPORTIVE CARE IN CANCER (2014)
Direct in Vitro Comparison of Daratumumab with Surrogate Analogs of CD38 Antibodies MOR03087, SAR650984 and Ab79
Jeroen Lammerts van Bueren et al.
BLOOD (2014)
Review of health-related quality of life data in multiple myeloma patients treated with novel agents
P. Sonneveld et al.
LEUKEMIA (2013)
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial
Michel Delforge et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools
Thomas R. Osborne et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma
Ann Kristin Kvam et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
M. Herdman et al.
QUALITY OF LIFE RESEARCH (2011)
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
A. Simon Pickard et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2007)
An internadional field study of the reliability and validity of a disease-specfic questionnanire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma
K. Cocks et al.
EUROPEAN JOURNAL OF CANCER (2007)
Share Paper
